Jones Cheryl A, Cunningham Anthony L
Herpesvirus Research Unit, & Department of Immunology and Infectious Diseases, The Children's Hospital at Westmead, Westmead, Australia.
Expert Rev Vaccines. 2003 Aug;2(4):541-9. doi: 10.1586/14760584.2.4.541.
Over five decades numerous conventional candidate live attenuated and killed vaccines have failed to prevent genital herpes in clinical trials. However, a vaccine consisting of recombinant glycoprotein D from herpes simplex virus (HSV)-2 and deacylated monophosphoryl lipid A adjuvant has recently shown partial efficacy against clinical disease transmitted from HSV-1 and -2 seronegative women (73-74%). Comparisons between the efficacy of this vaccine and previous failed candidates and their effects on the immune system should help guide development of better vaccines through selection of appropriate HSV proteins, adjuvants or cytokines and newer vaccine vectors, such as DNA vaccines, recombinant viral vaccines and specific HSV mutants.
五十多年来，众多传统的候选减毒活疫苗和灭活疫苗在临床试验中均未能预防生殖器疱疹。然而，一种由单纯疱疹病毒（HSV）-2的重组糖蛋白D和去酰化单磷酰脂质A佐剂组成的疫苗，最近在预防HSV-1和-2血清阴性女性传播的临床疾病方面显示出部分疗效（73%-74%）。比较这种疫苗与之前失败的候选疫苗的疗效及其对免疫系统的影响，应有助于通过选择合适的HSV蛋白、佐剂或细胞因子以及更新的疫苗载体（如DNA疫苗、重组病毒疫苗和特定的HSV突变体）来指导研发更好的疫苗。
